Kronox Lab Sciences has scheduled its 17th Annual General Meeting for September 16, 2026. The meeting will be held via video conferencing to transact ordinary and special business items.

The Board of Directors proposes a final dividend of ₹0.50 per equity share for the financial year ended March 31, 2026 (FY26). Shareholders will also consider the reappointment of Mr. Jogindersingh Jaswal as a director.

Key Agenda Items

The notice outlines specific resolutions for shareholder approval during the virtual meeting:

• Adoption of the Audited Standalone Financial Statements for FY26.
• Declaration of the final dividend.
• Reappointment of Mr. Jogindersingh Jaswal, who retires by rotation.
• Ratification of remuneration for Cost Auditors M/s. Diwanji & Associates.

Director Reappointment Details

Mr. Jogindersingh Jaswal seeks reappointment after serving since November 18, 2008. He holds a 26.39% stake in the company and draws an annual remuneration of ₹132 lakh. His expertise covers production, quality control, and human resources.

Cost Auditor Remuneration

The Board recommends ratifying the appointment of M/s. Diwanji & Associates as Cost Auditors for FY27. The proposed remuneration is fixed at ₹90,000 per annum plus applicable taxes. No directors or key managerial personnel have any financial interest in this resolution.

Meeting Logistics

The meeting will commence at 11:00 am on September 16, 2026. Remote e-voting will be available from September 13 to September 15, 2026. The cut-off date for voting rights is September 9, 2026. Share transfer books will remain closed from September 10 to September 16, 2026.

Indo Borax and Chemicals Limited has published the Detailed Public Statement (DPS) for its mandatory open offer to acquire a controlling stake in Kronox Lab Sciences . The acquirer aims to purchase up to 95,70,000 equity shares, representing 25.79% of the target’s voting share capital, at an offer price of ₹157.27 per share.

The DPS was published on August 28, 2026, by IIFL Capital Services Limited, acting as the manager to the open offer. The transaction follows a share purchase agreement dated August 20, 2026, wherein Indo Borax agreed to acquire 64.26% of Kronox Lab Sciences from its existing promoters. Zenrock Chemicals Private Limited acts as a person acting in concert (PAC) with the acquirer.

Offer Timeline

The tendering period for the open offer is scheduled to commence on October 15, 2026, and close on October 29, 2026. The last date for the dispatch of the Letter of Offer to public shareholders is October 8, 2026. Indo Borax must communicate acceptance or rejection of tendered shares by November 13, 2026.

Financial Arrangements

Indo Borax has confirmed firm financial arrangements to meet the obligations under the open offer. The acquirer holds cash and cash equivalents of ₹134.0 crore as of August 19, 2026. Additionally, the PAC, Zenrock Chemicals, has committed ₹25.0 crore in financial support. A total escrow amount of ₹38.0 crore, representing 25.25% of the maximum consideration, has been deposited with Kotak Mahindra Bank Limited.

Target Company Profile

Kronox Lab Sciences manufactures high-purity specialty fine chemicals for pharmaceutical, nutraceutical, and biotech sectors. The company reported total income of ₹1,064.1 crore and profit after tax of ₹276.6 crore for FY26. For the quarter ended June 30, 2026, revenue stood at ₹296.8 crore with a net profit of ₹73.0 crore.

What the Numbers Show

The disparity between the negotiated promoter exit price and the public offer price highlights a significant value transfer to minority shareholders. While the promoters sold their stake at an effective price of ₹105.87 per share, public shareholders are being offered ₹157.27 per share. This premium of approximately 49% over the negotiated price underscores the regulatory requirement to protect minority interests in substantial acquisitions, potentially leading to immediate arbitrage opportunities if the market price remains below the offer price during the tendering period.